Clinical Trial Update: Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study

View source ↗

Summary

A pilot trial investigating co-registration of 18F-FDG-PET and MRI for staging potentially resectable hilar cholangiocarcinoma was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholangiocarcinoma

Snippet

Sponsor: University of Toronto | Conditions: Cholangiocarcinoma | Status: WITHDRAWN